Get the Stockscreener App
0.8506
5.49%
-0.0494
After Hours:
.84
-0.0106
-1.25%
Nautilus Biotechnology Inc stock is traded at $0.8506, with a volume of 280.07K.
It is down -5.49% in the last 24 hours and up +20.31% over the past month.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
See More
Previous Close:
$0.90
Open:
$0.91
24h Volume:
280.07K
Relative Volume:
1.07
Market Cap:
$107.44M
Revenue:
-
Net Income/Loss:
$-70.78M
P/E Ratio:
-1.5189
EPS:
-0.56
Net Cash Flow:
$-61.27M
1W Performance:
-3.63%
1M Performance:
+20.31%
6M Performance:
+15.02%
1Y Performance:
-68.61%
1-Day Range:
$0.8197
$0.91
1-Week Range:
$0.8197
$0.93
52-Week Range:
$0.62
$3.026
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Name
Nautilus Biotechnology Inc
Sector
Industry
Phone
206-333-2001
Address
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
0.8506 | 113.67M | 0 | -70.78M | -61.27M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-02-21 | Initiated | Cowen | Outperform |
| Aug-04-21 | Initiated | Goldman | Neutral |
| Jul-13-21 | Initiated | Jefferies | Buy |
View All
Nautilus Biotechnology Inc Stock (NAUT) Latest News
Weiss Ratings Reaffirms Sell (D-) Rating for Nautilus Biotechnology (NASDAQ:NAUT) - MarketBeat
Will Nautilus Biotechnology Inc. price bounce be sustainableJuly 2025 Fed Impact & Accurate Buy Signal Notifications - newser.com
Should you hold or exit Nautilus Biotechnology Inc. now2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
Live market analysis of Nautilus Biotechnology Inc.Market Trend Review & Reliable Entry Point Alerts - newser.com
Published on: 2025-10-09 04:18:13 - newser.com
Will Nautilus Biotechnology Inc. see short term momentumFed Meeting & Reliable Price Action Trade Plans - newser.com
Is Nautilus Biotechnology Inc a good long term investmentMarket Entry Points & Smart Beta Strategies That Actually Work - earlytimes.in
Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025 - GlobeNewswire
Nautilus Biotechnology, Inc. to Announce Third Quarter 2025 Financial Results on October 28, 2025 - Quiver Quantitative
Nautilus Biotechnology to Participate in Upcoming September Investor Conferences - 富途牛牛
What institutional flow reveals about Nautilus Biotechnology Inc.2025 Institutional Moves & Community Consensus Picks - newser.com
Nautilus Biotechnology Inc. recovery potential after sell offJuly 2025 Fed Impact & Free Community Supported Trade Ideas - newser.com
Is now a turning point for Nautilus Biotechnology Inc.July 2025 Catalysts & High Accuracy Swing Trade Signals - newser.com
How sentiment analysis helps forecast Nautilus Biotechnology Inc.Weekly Stock Summary & Verified Entry Point Signals - newser.com
Nautilus Biotechnology Inc. stock daily chart insightsWeekly Profit Summary & Long Hold Capital Preservation Tips - newser.com
Detecting price anomalies in Nautilus Biotechnology Inc. with AI2025 Top Gainers & Fast Gaining Stock Reports - newser.com
Analyzing Nautilus Biotechnology Inc. with multi timeframe chartsJuly 2025 Opening Moves & Intraday High Probability Alerts - newser.com
What analysts say about Nautilus Biotechnology Inc stockFlag and Pennant Patterns & Exceptional Growth Investment - earlytimes.in
Goldman Sachs Group Inc. Has $148,000 Stock Position in Nautilus Biotechnology, Inc. $NAUT - Defense World
Nautilus Biotechnology (NASDAQ:NAUT) Trading Down 3.2% – Here’s Why - Defense World
Nautilus Biotechnology (NASDAQ:NAUT) Trading Down 3.2%Here's Why - MarketBeat
Price momentum metrics for Nautilus Biotechnology Inc. explained2025 Market Trends & Risk Adjusted Swing Trade Ideas - newser.com
Nautilus Biotechnology Inc Stock (NAUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nautilus Biotechnology Inc Stock (NAUT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Patel Sujal M | CEO, President, and Secretary |
Sep 08 '25 |
Buy |
0.68 |
83,500 |
57,031 |
10,341,721 |
| Murphy Matthew B. | General Counsel |
Sep 04 '25 |
Buy |
0.64 |
20,000 |
12,858 |
74,140 |
| Mowry Anna | CFO and Treasurer |
May 29 '25 |
Buy |
0.77 |
15,000 |
11,488 |
83,000 |
| Mallick Parag | Chief Scientist |
May 08 '25 |
Buy |
0.73 |
12,000 |
8,788 |
20,491,892 |
| Mallick Parag | Chief Scientist |
May 12 '25 |
Buy |
0.73 |
1,500 |
1,098 |
20,493,392 |
| Patel Sujal M | CEO, President, and Secretary |
Mar 19 '25 |
Buy |
0.99 |
53,300 |
53,028 |
10,117,788 |
| Patel Sujal M | CEO, President, and Secretary |
Mar 20 '25 |
Buy |
1.00 |
23,933 |
23,890 |
10,141,721 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):